Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial
Published 2 months, 2 weeks ago
Description
Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linked real-world data sets, and Melanie Whittington joins The Ron Lanton Report to argue biopharma policy needs to stay tethered to patients, not abstractions.